Sleep disorders and neurotic disorders in children represent a significant medical and social problem. The prevalence of insomnia in the pediatric population reaches 6%. When taking into account concomitant sleep disorders, this indicator increases to 50% among preschool children. Existing therapeutic approaches often require the development of new, safe, and effective remedies with improved compliance characteristics. The purpose of this scientific work is to develop and comprehensively study a new sedative phytopreparation in the form of chewable lozenges based on standardized extracts of Melissa officinalis (Melissa officinalis L.), Polemoniaceae (Polemonium caeruleum L.), and glycine. During the course of the work, the standardization of plant extracts was carried out, and a formulation and technology for producing lozenges were developed. The quality assessment was conducted based on organoleptic, physico-chemical, and microbiological parameters. The pharmacological activity was studied in preclinical studies on a model of white rats (n=30) using the "open field" and "raised cruciform maze" tests. The finished product meets the requirements of the regulatory documentation. Preclinical studies revealed a statistically significant (p<0.05) decrease in motor activity by 35% and an increase in the examination time of closed sleeves in the "raised maze" test by 40% compared with the control group.
